Introduction
Histological organization of MpBC
Cell origin of MpBC
Molecular alterations in MpBC
Molecular alteration | Description | Reference | Samplesize |
---|---|---|---|
Epithelial-to-mesenchymal transition (EMT) | -EMT core genetic signature shares similarity to core geneticsignatures of claudin-low and metaplastic breast cancers [20]. -MpBC tumors have more stem-like features, express highlevels of EMT markers, and share a similar genetic signature totumor-initiating cell (TIC) genetic signature [21]. -TICs are prominent following endocrine/chemotherapy, morechemoresistant, exhibit EMT, and can undergo self-renewal [22]. | Taube et al. [20] | 244 |
Hennessy et al. [21] | 28 | ||
Epidermal growth factor receptor(EGFR) signaling pathway | -34% of MpBC cases exhibit EGFR gene amplification associatedwith gene overexpression and no EGFR activating mutations [23, 24]. -Fluorescent in situ hybridization showed high EGFR copynumber secondary to aneusomy (22%) and amplification (4%) [25]. -Majority of MpBC is positive for p63 (59%), cytokeratin 5/6 (58%),KIT (24%), and EGFR (66%) overexpression [25]. | Reis-Filho et al. [23] | 25 |
Reis-Filho et al. [24] | 47 | ||
Gilbert et al. [25] | 38 | ||
Phosphoinositide 3-kinase (PI3K)signaling pathway | -47% of MpBC tumors harbor PIK3CA mutations and 5% have PTENdeletions [21]. 36.4% of HR+ breast cancers have PIK3CA mutations [26]. -Whole-exome sequencing analysis of MpBC tumors showedthe most altered genes were PIK3CA (29%), PIK3R1 (11%), FAT1(11%), ARID1A (11%), and PTEN (11%) [27]. -Next-generation sequencing of MpBC tumors showed themost commonly altered genes were TP53 (68.4%), PIK3CA(42.1%), and PTEN (15.8%) [28]. | Hennessy et al. [21] | 28 |
Razavi et al. [26] | 1918 | ||
Ng et al. [27] | 35 | ||
Afkhami et al. [28] | 21 | ||
Nitric oxide synthase (NOS)signaling pathway | -TNBC expresses high levels of nitric oxide (NO) than HER2+or luminal breast cancers and enhanced inducible nitric oxidesynthase (iNOS) expression is associated with worse prognosisand may confer resistance to chemotherapy [29]. -Inhibition of iNOS via L-NMMA in combination with docetaxelis more effective than docetaxel alone in enhancing tumorapoptosis, cell proliferation/migration, and reducing tumor-initiating capacity in TNBC and MpBC models. -39/40 (97.5%) of MpBC tumors harbor a RPL39 A14V oncogenicmutation, which is associated with enhanced NO activity, cancercell stemness, and lung metastasis [30]. | Granados-Principalet al. [29] | 83 |
Dave et al. [30] | 40 | ||
Wnt/β-catenin signaling | -Immunohistochemistry (IHC) of MpBC samples showed aberrant β-catenin expression in 33/36 (92% of cases), and mutational analysisshowed that 25.9% of MpBC tumors had CTNNB1 missense mutations,7.4% tumors had APC mutations, and 18.5% tumors had WISP3mutations [31]. -IHC of MpBC tumor samples reveals that β-catenin expressionhas more focal nuclear localization [32]. -MpBC tumors commonly harbor mutations in Wnt/β-cateninsignaling and PI3K/Akt signaling than TNBC tumors [27]. -The levels of CCN6 are low in MpBC, leading to enhancedinsulin-like growth factor 1 levels, EMT, invasion, metastasis, andbone morphogenic-4 signaling [8]. | Hayes et al. [31] | 26 |
Lacroix-Triki et al. [32] | 52 | ||
Ng et al. [27] | 35 | ||
Martin et al. [33] | – | ||
Programmed cell death protein 1 (PD-1)/programmed death ligand-1 (PD-L1) | -PD-L1 is expressed more in MpBC tumors (46%) relative to otherbreast tumor types (6% in HR+ and 9% in HER2+ breast cancers [34]. -Another study performed PD-L1 immunohistochemical staining of 21MpBC tumor samples and found that PD-L1 expression was associatedwith a worse RFS and OS [28]. -A patient with metastatic MpBC (PD-L1+ and with PIK3CAH1047L mutation) showed a dramatic response topembrolizumab in combination with nab-paclitaxel [35]. | Joneja et al. [34] | 290 |
Afkhami et al. [28] | 21 | ||
Adams 2017 [35] | 1 | ||
Cell cycle regulation | -MpBC tumors harbor a high frequency of TP53 (64%) and TERT(catalytic subunit of telomerase) promoter mutations (25%) [36] -TERT mutations are commonly found in the spindle andsquamous MpBC [36] -Myoepithelial MpBC shows a 9p21.3 chromosomal loss, including lossof genes CDK2NA and CDK2NB, which code for cyclin-dependent kinaseinhibitors p16INK4a and p15INK4b [37]. -64.3% of myoepithelial MpBC tumors with 9p21.3 loss alsohad a PIK3CA mutation [37]. | Krings and Chen [36] | 28 |
Bartels et al. [37] | 34 |
Epithelial-to-mesenchymal transition
Epidermal growth factor receptor (EGFR)
Phosphoinositide 3-kinase (PI3K) pathway
Nitric oxide signaling pathway
Wnt/β-catenin pathway
Programmed cell death protein 1 (PD-1)/programmed death ligand-1 (PD-L1)
Cell cycle regulating proteins
The role of systemic therapy
Radiation therapy
Potential therapies in clinical trials
Trial | Phase | Status |
---|---|---|
ARQule: ARQ751 (pan-AKT inhibitor) plus fulvestrant or paclitaxel compared to ARQ751 plus placebo in patients with breast or endometrial cancer harboring PIK3CA/AKT/PTEN mutations (NCT02761694) | 1b | Ongoing |
ARTEMIS: A clinical trial implementing diagnostic imaging + tumor genetic signature to predict sensitivity to standard-of-care versus personalized therapy. A non-randomized trial in which patients undergo baseline imaging and molecular testing of tumor biopsy. They receive standard anthracycline-based chemotherapy and undergo ultrasound imaging after cycles 2 and 4. After completing cycle 4 and obtaining molecular testing results, the patient may elect to continue standard chemotherapy or proceed to an experimental clinical trial designed to match tumor profile and TNBC subtype. Patients with tumors predicted to be resistant to standard chemotherapy are advised to participate in the experimental clinical trial (NCT02276443) | N/A | Ongoing |
L-NMMA (pan-nitric oxide synthase) inhibitor plus docetaxel in refractory locally advanced or metastatic TNBC patients (NCT02834403) | 1b/2 | Ongoing |
DART - Dual anti-CTLA4 and anti-PD1 blockade in rare tumors: Nivolumab (anti-CTLA4) antibody) plus ipilimumab (anti-PDL1 antibody) compared to nivolumab alone for patients with rare tumors, including MpBC (NCT02834013) | 2 | Ongoing |
Pembrolizumab (anti-PD1 antibody) plus nab-paclitaxel for TNBC and HR+/HER2− breast cancer cohorts (NCT02752685) | 2 | Ongoing |